PHARMACEUTICAL 2019

Lifecore Biomedical INC DE
Rank 127 of 361



PHARMACEUTICAL 2019

LANDEC

Lifecore Biomedical INC DE
Rank 127 of 361

The relative strengths and weaknesses of Lifecore Biomedical INC DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lifecore Biomedical INC DE compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 110% points.The greatest weakness of Lifecore Biomedical INC DE is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 101% points.

The company's Economic Capital Ratio, given in the ranking table, is 307%, being 57% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	97,063
Cost of Goods Sold	445,889
Intangible Assets	54,510
Liabilities, Current	88,375
Liabilities, Non-Current	37,360
Other Assets	93,530
Other Compr. Net Income	622
Other Expenses	-7,413
Other Liabilities	26,406
Other Net Income	3,923
Other Revenues	524,227
Property and Equipment	159,600
Research and Development	12,800
Selling, General and Administrative Expense	51,951

Output Variable	Value in 1000 USD
Assets	404,703
Liabilities	152,141
Expenses	503,227
Revenues	524,227
Stockholders Equity	252,562
Net Income	24,923
Comprehensive Net Income	25,234
BaseVar	794,422
ECR before LimitedLiability	207%
Economic Capital Ratio	307%